Vitamin D status and response to antiosteoporotic therapy.
Evaluation of: Adami S, Giannini S, Bianchi G et al.: Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos. Int. (2008) (Epub ahead of print). All recent osteoporosis guidelines recommend that patients taking treatments for osteoporosis (i.e., bisphosphonates) should be supplemented with vitamin D and calcium. However, the bone response (i.e., bone mineral density change and fractures incidence) to bisphosphonates therapy in relation to vitamin D intake in clinical practice is unknown. In a recent retrospective study, 1515 women with postmenopausal osteoporosis under antiresorptive treatment were classified as vitamin D deficient or vitamin D repleted, according to risk factors or the level of 25 hydroxy vitamin D above or below 50 nmol/l. The change in bone mineral density remained significantly higher in vitamin D-repleted compared with vitamin D-deficient women. Moreover, the adjusted odds ratio for incident fractures in vitamin D-deficient as compared with vitamin D-repleted women was 1.77 (95% CI: 1.20-2.59; p = 0.004).
Bruyere
Olivier
O
University of Liège, Department of Public Health, Epidemiology & Health Economics, CHU Sart-Tilman, Bât B23, 4000 Liège, Belgium. olivier.bruyere@ulg.ac.be
Reginster
Jean-Yves
JY
D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D001842:Bone and Bones / Q000187:drug effects; D002112:Calcifediol / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D015897:Comorbidity; D004164:Diphosphonates / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000453:epidemiology / Q000517:prevention & control*; D016896:Treatment Outcome; D014808:Vitamin D Deficiency / Q000188:drug therapy* / Q000453:epidemiology; D016387:Women's Health
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D002112:Calcifediol